Skip to main content
Top
Published in: Clinical Pharmacokinetics 1/2019

Open Access 01-01-2019 | short communication

The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models

Authors: Sebastiaan C. Goulooze, Swantje Völler, Pyry A. J. Välitalo, Elisa A. M. Calvier, Leon Aarons, Elke H. J. Krekels, Catherijne A. J. Knibbe

Published in: Clinical Pharmacokinetics | Issue 1/2019

Login to get access

Abstract

In covariate (sub)models of population pharmacokinetic models, most covariates are normalized to the median value; however, for body weight, normalization to 70 kg or 1 kg is often applied. In this article, we illustrate the impact of normalization weight on the precision of population clearance (CLpop) parameter estimates. The influence of normalization weight (70, 1 kg or median weight) on the precision of the CLpop estimate, expressed as relative standard error (RSE), was illustrated using data from a pharmacokinetic study in neonates with a median weight of 2.7 kg. In addition, a simulation study was performed to show the impact of normalization to 70 kg in pharmacokinetic studies with paediatric or obese patients. The RSE of the CLpop parameter estimate in the neonatal dataset was lowest with normalization to median weight (8.1%), compared with normalization to 1 kg (10.5%) or 70 kg (48.8%). Typical clearance (CL) predictions were independent of the normalization weight used. Simulations showed that the increase in RSE of the CLpop estimate with 70 kg normalization was highest in studies with a narrow weight range and a geometric mean weight away from 70 kg. When, instead of normalizing with median weight, a weight outside the observed range is used, the RSE of the CLpop estimate will be inflated, and should therefore not be used for model selection. Instead, established mathematical principles can be used to calculate the RSE of the typical CL (CLTV) at a relevant weight to evaluate the precision of CL predictions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1:e6.CrossRefPubMedPubMedCentral Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1:e6.CrossRefPubMedPubMedCentral
2.
go back to reference Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.CrossRefPubMedPubMedCentral Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development—part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.CrossRefPubMedPubMedCentral
3.
go back to reference Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci. 2017;109S:S22–6.CrossRefPubMed Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci. 2017;109S:S22–6.CrossRefPubMed
4.
go back to reference Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165(12):819–29.CrossRefPubMed Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr. 2006;165(12):819–29.CrossRefPubMed
5.
go back to reference Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32.CrossRefPubMed Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32.CrossRefPubMed
7.
go back to reference Knibbe CA, Brill MJ, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55:149–67.CrossRefPubMed Knibbe CA, Brill MJ, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M. Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol. 2015;55:149–67.CrossRefPubMed
8.
go back to reference Eleveld DJ, Proost JH, Absalom AR, Struys MM. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet. 2011;50(11):751–3 (discussion 5–6).CrossRefPubMed Eleveld DJ, Proost JH, Absalom AR, Struys MM. Obesity and allometric scaling of pharmacokinetics. Clin Pharmacokinet. 2011;50(11):751–3 (discussion 5–6).CrossRefPubMed
9.
go back to reference Mahmood I, Tegenge MA. Population pharmacokinetics: some observations in pediatric modeling for drug clearance. Clin Pharmacokinet. 2017;56(12):1567–76.CrossRefPubMed Mahmood I, Tegenge MA. Population pharmacokinetics: some observations in pediatric modeling for drug clearance. Clin Pharmacokinet. 2017;56(12):1567–76.CrossRefPubMed
10.
12.
go back to reference Calvier EA, Krekels EH, Valitalo PA, Rostami-Hodjegan A, Tibboel D, Danhof M, et al. Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade? Clin Pharmacokinet. 2017;56(3):273–85.CrossRefPubMed Calvier EA, Krekels EH, Valitalo PA, Rostami-Hodjegan A, Tibboel D, Danhof M, et al. Allometric scaling of clearance in paediatric patients: when does the magic of 0.75 fade? Clin Pharmacokinet. 2017;56(3):273–85.CrossRefPubMed
13.
go back to reference Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012;52(10):1601–6.CrossRefPubMed Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012;52(10):1601–6.CrossRefPubMed
15.
go back to reference Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. 2nd ed. New York: Springer; 2011.CrossRef Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. 2nd ed. New York: Springer; 2011.CrossRef
16.
go back to reference Snee RD, Marquardt DW. Comment: collinearity diagnostics depend on the domain of prediction, the model, and the data. Am Stat. 1984;38(2):83–7. Snee RD, Marquardt DW. Comment: collinearity diagnostics depend on the domain of prediction, the model, and the data. Am Stat. 1984;38(2):83–7.
17.
go back to reference Belsley DA. Demeaning conditioning diagnostics through centering. Am Stat. 1984;38(2):73–7. Belsley DA. Demeaning conditioning diagnostics through centering. Am Stat. 1984;38(2):73–7.
18.
go back to reference Voller S, Flint RB, Stolk LM, Degraeuwe PLJ, Simons SHP, Pokorna P, et al. Model-based clinical dose optimization for phenobarbital in neonates: an illustration of the importance of data sharing and external validation. Eur J Pharm Sci. 2017;109S:S90–7.CrossRefPubMed Voller S, Flint RB, Stolk LM, Degraeuwe PLJ, Simons SHP, Pokorna P, et al. Model-based clinical dose optimization for phenobarbital in neonates: an illustration of the importance of data sharing and external validation. Eur J Pharm Sci. 2017;109S:S90–7.CrossRefPubMed
19.
go back to reference Boeckmann AJ, Sheiner LB, Beal SL. NONMEM users guide—part VIII. Ellicott City: ICON Development Solutions; 2010. p. 220. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM users guide—part VIII. Ellicott City: ICON Development Solutions; 2010. p. 220.
20.
go back to reference Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:e50.CrossRefPubMedPubMedCentral Keizer RJ, Karlsson MO, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol. 2013;2:e50.CrossRefPubMedPubMedCentral
Metadata
Title
The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models
Authors
Sebastiaan C. Goulooze
Swantje Völler
Pyry A. J. Välitalo
Elisa A. M. Calvier
Leon Aarons
Elke H. J. Krekels
Catherijne A. J. Knibbe
Publication date
01-01-2019
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 1/2019
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-018-0652-7

Other articles of this Issue 1/2019

Clinical Pharmacokinetics 1/2019 Go to the issue